Headquarters: Leuven, Belgium
Founded: 2011
Website: icometrix.com
icometrix is a medical AI company specializing in quantitative brain MRI analysis for neurological conditions[1]. Founded in 2011 as a spinout from KU Leuven and UZ Leuven hospitals in Belgium, the company has become a leader in AI-powered neuroimaging analysis. Their FDA-cleared and CE-marked software products provide standardized, objective measurements of brain structures from MRI scans, supporting diagnosis and monitoring of multiple sclerosis (MS), Alzheimer's disease, and other neurological conditions.
| Feature | Description |
|---|---|
| Indication | Multiple sclerosis |
| Regulatory | FDA cleared, CE marked |
| Key Metrics | Lesion load, brain volume, atrophy progression |
icobrain is the company's flagship product for MS patients, providing automated analysis of MRI scans to detect and quantify white matter lesions, measure brain volume, and track changes over time[2]. The software integrates seamlessly into radiology workflows and provides actionable reports for clinicians.
| Feature | Description |
|---|---|
| Indication | Alzheimer's disease |
| Regulatory | FDA cleared, CE marked |
| Key Metrics | Hippocampal volume, ventricular volume, brain atrophy |
icobrain AD is specifically designed for Alzheimer's disease assessment, providing volumetric analysis of brain structures critical for Alzheimer's diagnosis and monitoring[3]. The software measures hippocampal atrophy, which is a key biomarker for AD progression, and provides standardized measurements that can be compared against normative databases.
| Feature | Description |
|---|---|
| Indication | Tau pathology research |
| Regulatory | Research use only |
| Key Metrics | Tau-related brain changes |
icobrain tau is an emerging product for tau pathology imaging analysis, currently available for research use. This tool analyzes PET and MRI data to detect tau protein accumulation patterns associated with Alzheimer's disease progression.
icometrix's imaging AI platform employs deep learning algorithms trained on large datasets of annotated MRI scans:
Volumetric Analysis
Lesion Segmentation
Longitudinal Tracking
icometrix has been validated in numerous clinical studies demonstrating:
icometrix is directly relevant to AD research and clinical care:
For Parkinson's disease patients[6]:
The original clinical focus of icometrix:
| Partner | Focus Area |
|---|---|
| Biogen | MS imaging biomarker partnership |
| Roche | Alzheimer's research collaboration |
| Merck | Digital health initiatives |
icometrix integrates with major radiology systems and picture archiving and communication systems (PACS), enabling seamless deployment in clinical workflows across hospitals and imaging centers.
The company collaborates with leading academic medical centers and research institutions on neuroimaging research and AI algorithm development.
| Product | FDA | CE Mark | Market |
|---|---|---|---|
| icobrain (MS) | 510(k) | Yes | Global |
| icobrain AD | 510(k) | Yes | Global |
| icobrain tau | Not cleared | Not cleared | Research only |
icometrix directly contributes to AD/PD research and clinical care:
Lyell D, et al. Clinical Correlation of Automated MRI Analysis in MS. Multiple Sclerosis Journal. 2020. ↩︎ ↩︎
Storey G, et al. icobrain AD validation in early-onset Alzheimer's disease. Alzheimer's & Dementia. 2018. ↩︎
de Sitter A, et al. Reproducibility of Automated Brain Volumetry across 3 Tesla scanner. NeuroImage. 2019. ↩︎
FDA. FDA 510(k) Clearance for icobrain. 2023. ↩︎
Archer D, et al. Brain volume changes in Parkinson's disease with dementia. Movement Disorders. 2021. ↩︎